Current Studies 

Research Trials

Declare TIMI Diabetes Mellitus

​

  • Provision of informed consent prior to any study specific procedures.

  • Female or male ages 40 years or older.

  • Diagnosed with Type 2 Diabetes
  • High Risk for Cardiovascular events



Bandera Family Health Care (BFHC) Research offers qualified participants the opportunity to receive new and innovative medications, treatments, and therapies through participation in clinical research trials. Here are some studies that you or someone you know might be interested in:

PFIZER



Merk Osteoporosis


  • Postmenopausal for 5 or more years.
  • Prior current treatment with oral bisphosphonate therapy for postmenopausal osteoporosis for 3 or more years.
  • BMD T-score at any hip site <-2.5 and >-3.5 as assessed by dual-energy X-ray absorptiometry (DXA) without a history of a prior fragility fracture.
  • Hydroxyvitamin D level >20 and <60ng/mL within 90 days of the time of randomization 

Merk Asthma


This is a 12 week study for subjects with persistent asthma. To qualify you must be: 


  • Between 18 and 75 years of age
  • Diagnosed with Asthma 
  • Be a nonsmoker 
  • Not suffering from COPD (Chronic Obstructive Pulmonary Disease).


Amarin Triglycerides

​

This is a five year study of highly purified fish oil component to evaluate efficacy of triglyceride control in reducing incidence of cardiovascular events. To qualify you must be:


  • Your fasting triglycerides must be between 135- 500 mg/dl
  • 4 weeks stable on statin with your LDL cholesterol between 40 and 100 mg/dl
  • Suffering from Type 2 diabetes
  • Over the age of 50 years

 And one of the following: 

  • Suffer from hypertension and taking medication 
  • Males over the age of 55
  • Females over 65 years of age 
  • Have microalbuminuria in the urine ​

OR 

  • Over the age of 45 with a record of Coronary Artery Disease. 

Carmelina 


  • ​Documented diagnosis of T2DM before Visit 1.
  • Male or female patients who are drug-naive or pretreated with any anti-diabetic background medication, excluding treatment with GLP-1 receptor agonist, DPP-4 inhibitors or SGLT-2 inhibitors if=> consecutive 7 days.
  • Stable antidiabetic background medication for at least 8 weeks prior to randomization compared with the daily insulin dose at randomization. 
  • HbA1c of =>6.5% and <=10% at Visit 1
  • Age=> 18 years at Visit 1. 
  • BMI <=45 kg/m2 at Visit 1
  • High Risk of CV event defined by:                  (1) albuminuria (micro or macro) and previous macrovascular disease and or (2) impaired renal function with predicted UACR.